CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023
Poolbeg Pharma PLC (AIM:POLB) Capital Markets Day
17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it
Poolbeg Pharma PLC (AIM:POLB) Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress Oral Vaccine Platform
Transformative oral vaccine platform funded by the Disruptive Technologies Innovation Fund
Poolbeg Pharma PLC (AIM:POLB) AI programme yields novel RSV drug targets
Artificial intelligence programme yields multiple novel RSV drug targets
TPI provides its latest research note on DeepVerge plc (DVRG.L).
DeepVerge has announced its new R&D service, which was launched in August 2020, has already generated £400,000 in completed sales in Q4 2020.
TPI provides its latest research note on DeepVerge plc (DVRG.L).
DeepVerge has announced breakthrough interim analysis that demonstrates its ability to host the SARS-CoV-2 virus on Labskin-cloned human skin microbiome.
TPI provides its latest research note on DeepVerge plc (DVRG.L).
As part of the extended field trial for DeepVerge’s Microtox PD unit, its COVID-19 enabled near-source wastewater contamination test system, deployment into a number ofIrish water treatment plants has now